Languages

Top Navigation (EN)

Soricimed Announces Presentations at the Upcoming American Association of Cancer Research (AACR) Annual Meeting

April 12, 2016

Soricimed Announces Presentations at the Upcoming
American Association of Cancer Research (AACR) Annual Meeting


TORONTO, Canada, April 12, 2016 – Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing peptide-based cancer therapeutics, is pleased to announce four poster presentations at the American Association of Cancer Research (AACR) annual meeting, taking place in New Orleans, April 16-20th. The presentations are based on pre-clinical and clinical research conducted on the company’s lead anti-cancer drug candidate SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel.

Cancer cell binding, internalization and intracellular localization of a novel therapeutic peptide SOR-C13 targeting the TRPV6 oncochannel
Abstract Number: LB-051
Session: Late-Breaking Research: Cancer Chemistry
Time: Sunday April 17, 1:00PM - 5:00PM.  
The company will present data demonstrating the anti-tumor targeting potential for the SOR-C series peptides specifically targeting the TRPV6 calcium channel, a novel target in oncology, over expressed in solid tumors cancers.

High prevalence of elevated TRPV6 mRNA in pancreatic ductal adenocarcinoma
Abstract Number: LB-128
Session: Late-Breaking Research: Clinical Research 1
Time: Monday April 18, 8:00AM-12:00PM.  
The presentation will focus on the high prevalence of elevated TRPV6 mRNA in pancreatic ductal adenocarcinoma.  TRPV6 is highly elevated in carcinomas including prostate, breast, lung and ovary and is correlated with poor outcomes. Phase I clinical trial results from SOR-C13 showed the potential of targeting TRPV6 in advanced adenocarcinomas of the pancreas.

A phase I open-label, dose escalation study of a novel peptide (SOR-C13) antagonistic to the TRPV6 ion channel in patients with advanced solid tumor cancers
Abstract Number: CT142
Session: Phase 1 Clinical Trials 2
Time: Wednesday, April 20, 8:00AM -12:00PM
Principal investigator Dr. Siqing Fu of MD Anderson Cancer Research Center will report the results of the Phase I clinical trial of SOR-C13, a first-in-man, selective, peptide inhibitor of Transient Receptor Potential Vanilloid 6 (TRPV6) calcium oncochannel. The objectives of the study were to assess safety and tolerability as well as the effect of SOR-C13 on solid cancers including lung, colon, breast and prostate cancers in patients that have failed conventional anti-cancer therapies.  

Soricimed’s collaborators will be presenting pre-clinical data on SOR-C13 in an additional poster.

TRPV6 calcium channel peptide antagonists as novel antimyeloma and antiresorptive agents
Abstract Number: 3791
Time: Tuesday, Apr 19, 2016, 1:00 PM - 5:00 PM
Session: Novel Targets
The presentation by Dr. Alli Murugesan (University of New Brunswick, Saint John, NB, Canada) reports the anti-myeloma and anti-osteoclast activity of human TRPV6 antagonist peptides (SOR-C13 and SOR-C27). Taken together, these findings suggest a novel therapeutic approach for multiple myeloma involving TRPV6 inhibition to target both myeloma cells and osteoclasts.

The AACR annual meeting is one of the largest gatherings of cancer researchers and oncologists in the world where upwards of 20,000 scientists, advocates, and healthcare professionals come together to learn about the latest breakthroughs in cancer science and what is happening on the frontlines to fight cancer.

About SOR-C13: SOR-C13 is a first-in-class peptide in development for the treatment of cancer. SOR-C13 binds with high selectivity and affinity to TRPV6, a calcium channel that is highly elevated in prostate, breast, lung and ovarian cancer and is correlated with poor outcomes. TRPV6-mediated Ca2+ entry is responsible for maintaining a high tumour proliferation rate, as well as increasing tumour cell survival and fortifying mechanisms that withstand cell destruction. By binding to this channel, SOR-C13 starves cancer cells of calcium that is needed for cell growth and division.  Due to the high specificity of SOR-C13 for its target and its unique mechanism of action this drug candidate may result in fewer and less severe side effects compared to standard cancer chemotherapy.  SOR-C13 is the first drug candidate targeting TRPV6 to have entered clinical development anywhere in the world.

Soricimed recently announced positive top-line results indicating safety, tolerability and potential activity in a Phase I trial of SOR-C13 in subjects with advanced solid tumour cancers.  Subjects were enrolled at Juravinski Cancer Centre, London Health Sciences Centre and the University of Texas MD Anderson Cancer Center. The FDA granted SOR-C13 orphan drug status for the treatment of ovarian cancers.

About Soricimed Biopharma:  Soricimed Biopharma Inc. is a private Canadian clinical-stage company developing novel cancer therapeutics and diagnostics.  Using focused, innovative strategies in collaboration with major world-class cancer research institutions, Soricimed’s drug candidates have demonstrated a capability to reduce cancer cell viability, induce apoptosis and to reduce human tumour volume while minimizing side-effects in various classic animal and in vitro tumour models. Soricimed recently announced positive top-line results indicating safety, tolerability and potential activity in a Phase I trial of SOR-C13 in subjects with advanced solid tumour cancers.  Additionally, Soricimed obtained orphan drug status for the treatment of ovarian cancers with SOR-C13. Privately held, Soricimed is funded through private investors and various programs from the Governments of Canada and New Brunswick. For more information please visit, www.soricimed.com.

Meet Soricimed at AACR

We look forward to discussing the latest results of SOR-C13, a first-in-class TRPV6 antagonist in development for the treatment of solid-tumor cancer. If you wish to meet us at the AACR meeting please do not hesitate to contact us via Julie.fotheringham@hageman.ca.

For More Information:
Julie Fotheringham - Partner, Hageman Communications
Julie.fotheringham@hageman.ca
416-951-7988